**Abstract**

**Background:** This aim of this study was to determine the impact of fluvoxamine, an inhibitor of CYP2C19, on the pharmacokinetics of escitalopram, a substrate of CYP2C19.

**Methods:** Thirteen depressed patients initially received a 20 mg/day dose of escitalopram alone. Subsequently, a 50 mg/day dose of fluvoxamine was administered due to the insufficient efficacy of escitalopram. Plasma concentrations of escitalopram and desmethylescitalopram were quantified using HPLC before and after fluvoxamine co-administration. The QT and corrected QT (QTc) intervals were measured before and after fluvoxamine co-administration.

**Results:** Fluvoxamine significantly increased the plasma concentrations of escitalopram (72.3±36.9 ng/ml versus 135.2±79.7 ng/ml, p\<0.01) but not those of desmethylescitalopram (21.5±7.0 ng/ml versus 24.9±12.0 ng/ml, ns). The ratios of desmethylescitalopram to escitalopram were significantly increased during fluvoxamine co-administration (0.37±0.21 ng/ml versus 0.21±0.10, p\<0.01). The CYP2C19 genotype did not fully explain the degree of the change. Fluvoxamine co-administration did not change the QT or QTc intervals.

**Conclusions:** The results of the present study suggest that adjunctive treatment with fluvoxamine increases the concentration of escitalopram. The QTc interval did not change in this condition.
